Previous 10 | Next 10 |
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it is sponsoring The Sun Bus , a community service provided by the Colorado Melanoma...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the Society for Investigative Dermatology ’s (SID) annual meet...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its commendation and support for the Biden Administration’s reignited Cancer Moonsho...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the return of its #Stickit2Melanoma campaign in honor of Melanoma and Skin Cancer Awareness M...
Cowen analyst Max Masucci lowered the firm's price target on DermTech (DMTK -11.4%) to $20 from $33 and keeps an Outperform rating on the shares. The analyst said the company delivered a solid beat on billable volumes in Q1 which is a positive sign that productivity in its expanded commercial...
DermTech, Inc. (DMTK) Q1 2022 Earnings Conference Call March 3, 2022, 5:00 PM ET Company Participants John Dobak – President and Chief Executive Officer Kevin Sun – Chief Financial Officer Steve Kunszabo – Senior Director Investor Relations Conference Call Participants Br...
Shares of DermTech (NASDAQ:DMTK) are up 7% in after-hours trading even though the molecular diagnostic company's Q1 2022 results missed on top and bottom lines. Net loss nearly doubled to $30.1M (-$1.01 per share) compared to $15.1 million (-$0.55 per share) in the year-ago per...
DermTech press release (NASDAQ:DMTK): Q1 GAAP EPS of -$1.01 misses by $0.12. Revenue of $3.7M (+46.8% Y/Y) misses by $0.05M. 2022 Outlook: The Company affirmed its full-year 2022 outlook for assay revenue between $22 million and $26 million. Cash, cash equivalents, restricted cash and short-t...
- Record billable sample volume and assay revenue DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2022 financial resu...
ABNB, ACHC, ADC, AHT, AIG, AIZ, AKAM, ALR, AMCR, AMD, ANDE, APPH, AQST, ATEN, AYX, BFAM, BGFV, BLKB, BNFT, BNL, BTG, BXC, CGBD, CHCT, CNDT, CNR, COKE, CRK, CRUS, CTSO, CWH, CZR, DENN, DHC, DMTK, EGY, EHTH, EIX, ENLC, ENVA, EQX, EXR, FLGT, FPI, FRSH, GLAD, GLRE, GNW, GPOR, GRBK, HASI, HLF, HRZ...